



Management's Discussion & Analysis

For the three and nine-month periods ended December 31, 2022

TABLE OF CONTENTS

Table of Contents	i
Preliminary Notes	ii
Company Overview	1
Selected Financial Information	3
Highlights for Three- and Nine-Month Periods Ended December 31, 2022	5
Discussion of Operations	9
Summary of Quarterly Results	13
Company Strategy and Outlook	15
Liquidity and Capital Resources	18
Off-Balance Sheet Arrangements	22
Transactions with Related Parties	22
Reconciliation of Adjusted Net Income (Loss) and Adjusted EBITDA to Net Income (Loss)	23
Critical Accounting Estimates, Judgments, and Assumptions	25
Financial Instruments and Other Instruments	25
Disclosure of Outstanding Share Data	26
Risk Factors and Risk Management	29
Controls and Procedures	29
Additional Information	30

PRELIMINARY NOTES

This management's discussion and analysis of financial position and results of operations (**MD&A**) of Medexus Pharmaceuticals Inc. and its subsidiaries (collectively **Medexus** or **Company**) relates to the three- and nine-month periods ended December 31, 2022. It was approved by Medexus's board of directors (**Board**) on February 8, 2023.

The unaudited condensed interim consolidated financial statements of Medexus for the three- and nine-month periods ended December 31, 2022 were prepared in accordance with International Financial Reporting Standards (**IFRS**) as issued by the International Accounting Standards Board (**IASB**). This MD&A should be read in conjunction with Medexus's audited consolidated financial statements and most recently filed annual information form (**AIF**).

Unless the context otherwise requires, all financial information in this MD&A is presented on an IFRS basis and all amounts are presented in United States dollars.

Forward-looking statements

Certain statements in this MD&A contain forward-looking information within the meaning of applicable securities laws (**forward-looking statements**). Such forward-looking statements include statements that express or involve discussions as to expectations, beliefs, plans, objectives, assumptions, or future events or performance, and which are not historical facts. Forward-looking statements are often, but not always, indicated by words or phrases such as "anticipates", "believes", "budget", "could", "estimates", "expects", "forecasts", "goals", "intends", "may", "might", "objective", "outlook", "plans", "projects", "schedule", "should", "will", "would" and "vision". All forward-looking statements in this MD&A are expressly qualified by the cautionary statements in this section.

Specific forward-looking statements in this MD&A include, but are not limited to, information contained in statements regarding any of the following: Medexus's business strategy, outlook, and other expectations regarding financial or operational performance; anticipated trends and challenges in Medexus's business and the markets in which it operates, including the company's competitive position in and demographics of those markets; Medexus's expectations and plans regarding future growth and revenues (including in respect of IXINITY and other leading products described in this MD&A) and ability to pay dividends and distributions; Medexus's expectations regarding the business strategies of its competitors; the timing of a trial court decision in respect of, and any outcome of, the Metoject Litigation (defined below); Medexus's expectations regarding availability of funds from operations, cash flow generation, and capital allocation, and anticipated cash needs, capital requirements, and needs for additional financing; Medexus's ability to secure and fund commercialization rights to promising products and the performance of those products against expectations; the ability of Medexus and its business partners to secure regulatory approvals from the U.S. Food and Drug Administration (**FDA**), Health Canada, and other agencies when required; and the potential ongoing impact of the Covid-19 pandemic (including any variants) and Medexus's response, including any balance-sheet and cost management strategies and any benefits from those strategies. In addition, forward-looking statements in this MD&A also include statements regarding the potential benefits of treosulfan and the occurrence, timing, and expected outcome of the FDA review process for treosulfan, including any related collection and submission of information to the FDA and the FDA's acceptance and review of that information,

and a related launch of the product in the United States and expectations regarding the product's prospects if approved by the FDA.

The forward-looking statements and information included in this MD&A are based on Medexus's current expectations and assumptions. Although Medexus believes that such expectations and assumptions are reasonable, readers of this MD&A should not place undue reliance on the forward-looking statements and information in this MD&A because Medexus can give no assurance that they will prove to be correct. Forward-looking statements and information involve inherent risks and uncertainties because they address future events and conditions. Actual results could differ materially from those currently anticipated by Medexus as a result of a number of factors, risks and uncertainties. Relevant risks and uncertainties include, among other things, the uncertainties inherent in research and development conducted by Medexus or, more frequently, its business partners, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data relating to product candidates are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies of a given product candidate; whether and when drug applications may be filed in a given market for the relevant product; whether and when any such applications may be approved by regulatory authorities, which will depend on many factors, including making a determination as to whether the product candidate's benefits outweigh its known risks and determination of the product candidate's efficacy; decisions by regulatory authorities impacting labeling, manufacturing processes, safety, and/or other matters that could affect the availability or commercial potential of the product; and, if approved, whether the product will be commercially successful, including as a result of competitive developments. A further description of material risk factors that could cause actual results or events to differ materially from those expressed in Medexus's forward-looking statements can be found under the heading "Risk Factors and Risk Management" in this MD&A and "Risk Factors" in Medexus's most recent AIF. In addition, new factors and risks that affect Medexus can emerge from time to time. It is not possible for management to predict all such factors and risks and to assess in advance the impact of each such factor or risk on Medexus's business, or the extent to which any factor or risk, or combination of factors or risks, may cause actual results to differ materially from those contained in any of Medexus's forward-looking statements.

Unless otherwise noted, any forward-looking statement speaks only as of the date of this MD&A. Except as expressly required by applicable law, Medexus does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which that forward-looking statement is made or to reflect the occurrence of unanticipated subsequent events.

Non-GAAP measures

Company management uses, and this MD&A refers to, financial measures that are not recognized under IFRS and do not have a standard meaning prescribed by generally accepted accounting principles (**GAAP**) in accordance with IFRS or other financial or accounting authorities (**non-GAAP measures**). These non-GAAP measures may include "non-GAAP financial measures" and "non-GAAP ratios" (each defined in National Instrument 52-112, *Non-GAAP and Other Financial Measures Disclosure*). Medexus's method for calculating these measures may differ from

methods used by other companies and therefore these measures are unlikely to be comparable to similarly-designated measures used or presented by other companies. Medexus believes that these non-GAAP measures complement its IFRS measures and provide additional insight into, and allow for a more complete understanding of, the company's financial and operational results and management's perspective on Medexus's business and operations.

In particular, management uses Adjusted Net Income (Loss) and Adjusted EBITDA as measures of Medexus's performance. Adjusted Net Income (Loss), EBITDA (earnings before interest, taxes, depreciation, and amortization) and Adjusted EBITDA are non-GAAP financial measures. In addition, Adjusted Net Income (Loss) is presented in this MD&A on a per share basis. Adjusted Net Income (Loss) per Common Share is a non-GAAP ratio and is calculated by dividing Adjusted Net Income (Loss) by the weighted average number of Common Shares outstanding during the applicable period.

Medexus considers Adjusted Net Income (Loss) and Adjusted EBITDA to be key metrics in assessing business performance and an important measure of operating performance and cash flow. However, Medexus's non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of Medexus's financial information as reported under IFRS.

A further explanation and discussion of each of these non-GAAP measures, including their limitations, is set out below. A reconciliation of each of these non-GAAP measures to the most directly comparable IFRS measure can be found under the heading "Reconciliation of Adjusted Net Income (Loss) and Adjusted EBITDA to Net Income (Loss)".

Adjusted Net Income (Loss)

Medexus defines **Adjusted Net Income (Loss)** as net income (loss), determined under IFRS, before unrealized loss (gain) on the change in fair value of the embedded derivatives in Medexus's 6% unsecured convertible debentures due 2023 (**Convertible Debentures**).

The Convertible Debentures are a compound financial instrument under IAS 32, *Financial Instruments: Presentation*, and have both a liability and an embedded derivative component. The fair value of the consideration for the compound instrument must be split into its liability and derivative components. The derivative is measured at fair value through profit or loss, and its fair value must be measured at each reporting period with subsequent changes in fair value recorded in the consolidated statement of loss. This non-cash value is sensitive to, among other things, fluctuations in Medexus's share price, which is largely outside management's control and subject to external factors. In addition, several key assumptions affect the results of this calculation, including estimated share price volatility. Medexus uses a derivative valuation model to estimate the fair value of the derivative at the inception date and again at subsequent reporting dates. The most significant assumption used in this model is the discount rate to fair value for the liability component of the Convertible Debentures. Several other assumptions affect the results of this calculation, including estimated share price volatility.

Adjusted Net Income (Loss) adjusts net income (loss) to exclude these non-cash unrealized losses (gains). Medexus believes that Adjusted Net Income (Loss) provides a better representation of Medexus's performance because it excludes these non-cash fair value adjustments on unrealized liabilities that are largely outside management's control and that Medexus can settle for shares.

Adjusted EBITDA

Medexus defines **Adjusted EBITDA** as net income (loss), or earnings, adjusted to exclude interest income and expense, income tax recovery and expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation, financing and special transaction costs (for clarity, including fees related to acquisitions and related financings), termination benefits, foreign exchange gains or losses, unrealized gain or loss on the fair value of the embedded derivatives in the Convertible Debentures, unrealized gain or loss on the fair value of amounts payable in connection with business combination transactions, income from sale of assets, and impairment of intangible assets.

Medexus believes that Adjusted EBITDA, when used in conjunction with IFRS financial measures, is a useful supplemental measure of operating performance because Medexus believes that Adjusted EBITDA corresponds more closely over time to the performance of the company's underlying business assets. In particular, Medexus believes that Adjusted EBITDA facilitates comparisons of historical performance by excluding non-cash items (such as stock-based payments, fair value adjustments, and impairment charges) and other amounts not directly attributable to the company's primary operations (such as the impact of acquisitions, dispositions, and settlements).

Company management and the Board also use this non-GAAP measure to develop internal budgets and evaluate the performance of the company and its management team.

Key limitations to using Adjusted EBITDA include the following –

- Adjusted EBITDA does not reflect the cash requirements necessary to service interest or principal payments on Medexus's debt, that may be required to pay the company's taxes, that Medexus pays in connection with financing and special transactions, or that Medexus pays to former employees as termination benefits.
- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for those potential future replacements.
- Although stock-based compensation expenses are non-cash charges, Medexus relies on equity instruments to compensate and incentivize company directors, officers, and employees, and expects to continue doing so in the future.
- Although adjusting for the fair value of the embedded derivatives in the Convertible Debentures and the fair value of amounts payable in connection with business combination transactions are non-cash adjustments, these charges generally reflect the present value of amounts that Medexus may be required to pay in Common Shares.

Trademarks and trade names

This MD&A contains references to trademarks and service marks, including those belonging to other companies, persons, or entities. Solely for convenience, trademarks and trade names referred to in this document may appear without the "®" or "™" symbols. Each such reference should be read as though it appears with the relevant symbol. Any such references are not intended to indicate, in any way, that the holder or holders of the relevant intellectual property

rights will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names.

COMPANY OVERVIEW

Medexus is a leader in innovative rare-disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Medexus's experienced management team has a long and proven track record of successfully sourcing, developing, and commercializing pharmaceutical products in a variety of therapeutic areas at all stages of their life cycle throughout the United States and Canada.

Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, and allergy. Medexus continues to build a highly differentiated company with a growing portfolio of innovative high-value orphan drug and rare disease products that will underpin the company's future growth.

Medexus's current leading products are –

- IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood which is necessary to control bleeding;
- Rasuvo (U.S.) and Metoject (Canada), a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases;
- Rupall, an innovative prescription allergy medication with a unique mode of action; and
- Gleolan (aminolevulinic acid hydrochloride or ALA HCl), an optical imaging agent with orphan drug designation in the United States, currently indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery.

These existing products have primarily driven Medexus's performance to date.

Medexus also actively pursues opportunities to complement its existing product portfolio by licensing and acquiring new products. For example, in March 2022, Medexus entered into a license, supply, and distribution agreement under which Medexus acquired the exclusive right to commercialize Gleolan in the United States. In August 2022, Medexus completed a seamless transition to full commercial responsibility for Gleolan and began shipping Medexus-labeled product to customers across the United States. This transaction complemented Medexus's existing commercialization rights to Gleolan in Canada, where Medexus executed a full commercial launch of Gleolan in February 2021. For more information about Medexus's products and programs, see "Narrative Description of Medexus's Business—Core products and programs" in the AIF.

Medexus believes that its existing commercialization infrastructure will benefit from leverage effects as Medexus continues optimizing the company's product portfolio. Medexus therefore regularly explores additional complementary product opportunities in both current and planned therapeutic areas in both the United States and Canada, and regularly evaluates various transaction opportunities based on the company's strategic plan. The company's current objective is to execute near-term accretive transactions to achieve its growth targets over the coming years to deliver strong financial results for the company and its investors.

Medexus believes that the company offers a scalable commercial platform that can provide significant revenue and earnings potential. To achieve this objective, Medexus continues striving to increase revenue, develop and leverage the company's commercialization infrastructure across products, realize synergies across the company's predecessor companies, and maintain strict financial discipline.

SELECTED FINANCIAL INFORMATION

(Amounts in \$ '000s)

Three-Month Periods Ended December 31	2022	2021	2020
	\$'000	\$'000	\$'000
Revenue	28,731	21,270	24,256
Cost of goods sold	12,798	9,769	11,599
Gross profit	15,933	11,501	12,657
Selling and administrative expense	11,878	10,679	9,379
Research and development	693	1,035	1,155
Transaction-related fees	–	33	448
Termination benefits	372	–	–
Operating income (loss)	2,900	(339)	1,544
Net loss	(1,507)	(1,150)	(12,783)
Adjusted net loss*	(861)	(3,389)	(417)
Adjusted EBITDA*	5,223	1,916	3,915
Basic net loss per share	(0.07)	(0.07)	(0.88)
Diluted net loss per share	(0.07)	(0.07)	(0.88)
Total assets	146,320	138,131	138,262
Total non-current liabilities	30,086	68,350	85,851
Cash used by operating activities	(2,204)	(1,718)	(2,182)
Cash used by investing activities	(538)	(353)	(752)
Cash provided by financing activities	2,416	3,477	5,743

* See "Preliminary Notes—Non-GAAP measures" and "Reconciliation of Adjusted Net Income (Loss) and Adjusted EBITDA to Net Income (Loss)".

SELECTED FINANCIAL INFORMATION

(Amounts in \$ '000s)

Nine-Month Periods Ended December 31	2022	2021	2020
	\$'000	\$'000	\$'000
Revenue	79,463	56,438	62,021
Cost of goods sold	34,442	28,625	28,829
Gross profit	45,021	27,813	33,192
Selling and administrative expense	36,864	34,140	25,920
Research and development	2,210	5,039	2,580
Transaction-related fees	172	33	448
Termination benefits	610	784	680
Operating income (loss)	4,880	(12,492)	3,190
Net income (loss)	(5,635)	2,408	(17,774)
Adjusted net loss*	(7,341)	(19,357)	(2,468)
Adjusted EBITDA*	11,326	(5,012)	9,794
Basic net income (loss) per share	(0.28)	0.12	(1.23)
Diluted net income (loss) per share	(0.28)	0.11	(1.23)
Total assets	146,320	138,131	138,262
Total non-current liabilities	30,086	68,350	85,851
Cash provided (used) by operating activities	(5,307)	(4,962)	835
Cash used by investing activities	(1,026)	(6,359)	(1,314)
Cash provided by financing activities	5,807	2,203	4,380

* See "Preliminary Notes—Non-GAAP measures" and "Reconciliation of Adjusted Net Income (Loss) and Adjusted EBITDA to Net Income (Loss)".

HIGHLIGHTS FOR THREE- AND NINE-MONTH PERIODS ENDED DECEMBER 31, 2022

The following describes highlights in Medexus's financial and operating performance for the three- and nine-month periods ended December 31, 2022.

Financial Highlights

Medexus remains focused on delivering strong revenue growth and improved overall performance across the company's portfolio of products in both the United States and Canada, and saw continued strength and stability in the company's base business.

- Medexus achieved record revenue of \$28.7 million and \$79.5 million for the three- and nine-month periods ended December 31, 2022, an increase of \$7.4 million and \$23.1 million, or 34.7% and 41.0%, compared to \$21.3 million and \$56.4 million for the three- and nine-month periods ended December 31, 2021. The revenue increase was primarily attributable to increases in net sales across Medexus's portfolio, including recognition of 100% of revenue from Gleolan sales in the United States starting September 2022.
- Medexus achieved record Adjusted EBITDA of \$5.2 million and \$11.3 million for the three- and nine-month periods ended December 31, 2022, an increase of \$3.3 million and \$16.3 million compared to the three- and nine-month periods ended December 31, 2021. See "Preliminary Notes—Non-GAAP measures" and "Reconciliation of Adjusted EBITDA to Net Income (Loss)". The Adjusted EBITDA increase was primarily attributable to the increases in net sales mentioned above, a reduction in research & development costs, and an increase in gross margin.

Additional financial highlights for the three- and nine-month periods ended December 31, 2022 include the following –

- Available liquidity of \$10.1 million (December 31, 2022) compared to \$11.2 million (March 31, 2022). See "Liquidity and Capital Resources".
- Net loss of \$1.5 million and \$5.6 million for the three- and nine-month periods ended December 31, 2022, an increase of \$0.3 million and a decrease of \$8.0 million compared to a net loss of \$1.2 million and net income of \$2.4 million for the three- and nine-month periods ended December 31, 2021.
- Adjusted net loss of \$0.9 million and \$7.3 million for the three- and nine-month periods ended December 31, 2022 compared to \$3.4 million and \$19.4 million for the three- and nine-month periods ended December 31, 2021, an improvement of \$2.5 million and \$12.1 million. Adjusted net loss is adjusted for the non-cash unrealized gain of \$0.6 million and \$1.7 million for the three- and nine-month periods ended December 31, 2022 and \$2.2 million and \$21.8 million for the three and nine-month periods ended December 31, 2021. See "Preliminary Notes—Non-GAAP measures" and "Reconciliation of Adjusted Net Income (Loss) and Adjusted EBITDA to Net Income (Loss)".
- Current liabilities of \$100.8 million (December 31, 2022) compared to \$48.1 million (March 31, 2022) as the loans under the Credit Agreements (defined below) and the Convertible Debentures will mature within the next 12 months. Medexus continues to evaluate the

company's capital structure and is making progress on securing options to manage these near-term liabilities. See "Liquidity and Capital Resources".

Operational Highlights

Product highlights

Leading products

IXINITY

Unit demand in the United States remained strong during the three-month period ended December 31, 2022 and the trailing 12-month period ended December 31, 2022 – reflecting new patient conversions on top of a stable, existing base of patients, following resumption of in-person selling earlier in the year. (Source: customer-reported dispensing data.) Medexus has also continued to improve the IXINITY manufacturing process, which has had a positive impact on manufacturing costs.

Rasuvo

The company maintained its market leading position during the three-month period ended December 31, 2022, with an estimated 80% unit share during the trailing 12-month period ended December 31, 2022, as unit demand for Rasuvo remained strong in the moderately-growing U.S. branded methotrexate market with a limited sales force allocation. (Source: Symphony Sub National 12/31/2022 Data & Chargebacks, PAP). However, increasing competition in the U.S. branded methotrexate market continues to adversely affect Rasuvo product-level revenue.

Rupall

Unit demand in Canada remained strong during the three-month period ended December 31, 2022 which was reflected in the unit demand growth of 25% for the trailing 12-month period ended December 31, 2022. (Source: IQVIA CDH units – Drugstores and hospitals purchases, MAT December 2022.) This strong performance reflects successful execution of the company's sales and marketing initiatives over the five years since launch.

Gleolan (United States)

Unit demand continues to be in line with expectations, positioning Medexus to successfully execute its post-transition commercial plan including new sales and marketing initiatives. The company began shipping Medexus-labeled product to customers across the United States in August, meaning that September 2022 was the first full month, and the three-month period ended December 31, 2022 was the first full fiscal quarter, in which Medexus recognized 100% of Gleolan net sales.

Metoject

Unit demand in Canada increased during the three-month period ended December 31, 2022 and the trailing 12-month period ended December 31, 2022. (Source: IQVIA – TSA database). However, product-level performance continues to experience disruption from the launch of a generic product in the Canadian methotrexate market in calendar year 2020.

In August 2020, Medexus and medac, licensor of Medexus's commercialization rights to market and sell Metoject in Canada, commenced a patent litigation in Canada's Federal Court relating to two generic versions of Metoject in Canada (**Metoject Litigation**). The trial was completed in

January 2023, and Medexus anticipates that the Federal Court will issue its decision later in calendar year 2023. For more information about the Metoject Litigation, see the AIF.

Product pipeline highlights

Treosulfan (United States)

In September 2022, Medexus was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the FDA had delivered to medac a second notice of incomplete response regarding medac's July 2022 new drug application resubmission for treosulfan (**NDA**), following the FDA's May 2022 notice of incomplete response and July 2021 complete response letter to medac. medac, as the party responsible for regulatory matters under Medexus's license agreement for treosulfan, has continued to engage with the FDA regarding medac's resubmission of the NDA. medac's engagement has primarily focused on establishing the most appropriate approach to addressing the remaining items noted in FDA's second notice of incomplete response. The FDA continues to seek supporting information from medac relating to the pivotal phase 3 clinical trial of treosulfan conducted by medac.

Based on Medexus's assessment of the FDA's feedback and discussions with medac, Medexus expects that it would take medac up to a year or more to collect and submit the information requested by the FDA. The FDA would then evaluate the completeness of the available information submitted and medac's response and, if considered to be complete, then proceed to review medac's NDA resubmission.

Medexus believes that treosulfan would make a substantial difference for US patients and therefore continues to urge medac to take the steps necessary to respond to the FDA's requests in a timely and complete fashion. Medexus has applied much of the infrastructure added in anticipation of a treosulfan launch to support Gleolan, gaining experience in many of the same institutions that are expected to use treosulfan if and when it is approved. Medexus also implemented a restructuring plan in October 2022 to focus resources on existing products.

IXINITY (pediatric study)

Medexus continues to explore opportunities to expand the patient population eligible to use IXINITY. In the first half of calendar year 2023, Medexus expects to submit to the FDA the results of Medexus's phase 4 clinical trial evaluating the safety and efficacy of IXINITY in previously treated patients under 12 years of age with hemophilia B. Successfully expanding the indicated patient population, together with reductions in associated manufacturing costs, could also render the product suitable for commercialization in other markets under out-licensing or other arrangements.

Gleolan (meningioma indication)

The licensor of Medexus's commercialization rights to Gleolan continues to pursue research and development activities regarding a meningioma indication for Gleolan (aminolevulinic acid hydrochloride or ALA HCl). Medexus's exclusive commercialization rights include this additional meningioma indication.

Triamcinolone Hexacetonide (United States)

In December 2020, Medexus entered into an exclusive license, distribution, and supply agreement with Laboratoires Ethypharm to register and commercialize Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (**TH**) in the United States. Medexus is currently

evaluating the most expedient path to an FDA approval which would allow for a full commercial launch of this product. If approved by the FDA, Medexus expects that commercialization of TH would have a moderately positive impact on the company's total revenue.

Other highlights

New board members

In February 2023, Harmony P. Garges MD MPH and Menassie Taddese MBA were appointed to the Board to fill two newly created directorships with effect as of February 6, 2023 and will initially serve until the next annual meeting of Medexus shareholders.

Amendment to Relaxa license agreement

In December 2022, Medexus signed an amendment to its exclusive license agreement for Relaxa. The amendment permits Medexus to pay in common shares up to 80% of the closing consideration due in connection with any exercise of Medexus's right to acquire, or the third-party licensor's option to sell, the Relaxa product rights as provided in the Relaxa license agreement. For more information about the Relaxa license agreement, see "Material Contracts" in the AIF.

DISCUSSION OF OPERATIONS

The following section discusses Medexus's results of operations for the three- and nine-month periods ended December 31, 2022 compared to the three- and nine-month periods ended December 31, 2021.

Revenue

(Amounts in millions)	Three-month periods ended December 31			Nine-month periods ended December 31		
	2022	2021	Change	2022	2021	Change
	Revenue	\$28.7	\$21.3	34.7%	\$79.5	\$56.4

The \$7.4 million and \$23.1 million increase in total revenue for the three and nine-month periods ended December 31, 2022 compared to the three- and nine-month periods ended December 31, 2021 was primarily attributable to increases in net sales across Medexus's portfolio, including recognition of 100% of revenue from Gleolan sales in the United States starting September 2022.

Net sales of IXINITY were lower during the nine-month periods ended December 31, 2021, as pharmacy and wholesale customers worked through inventory on hand. However, pharmacy and wholesale customers have now returned to buying patterns better aligned with patient unit demand. In addition, revenue for the three- and nine-month periods ended December 31, 2021 did not include revenue from Gleolan sales in the United States, a portion of which (determined in accordance with the Gleolan license agreement) Medexus has recognized since March 2022, when Medexus acquired the exclusive right to commercialize Gleolan in the United States.

Gross profit and gross margin

(Amounts in millions)	Three-month periods ended December 31			Nine-month periods ended December 31		
	2022	2021	Change	2022	2021	Change
	Gross profit	\$15.9	\$11.5	38.3%	\$45.0	\$27.8
Gross margin	55.4%	54.1%	130 bps	56.6%	49.3%	730bps

The \$4.4 million and \$17.2 million increase in gross profit and 130bps and 730bps increase in gross margin for the three- and nine-month periods ended December 31, 2022 compared to the three- and nine-month periods ended December 31, 2021 reflects the increases in revenue discussed above, including the relative contribution of product-level net sales, and the impact of failed batches of IXINITY, the manufacturing process for which is highly sensitive to deviations from product specifications, during the three- and nine-month periods ended December 31, 2021.

In general, gross profit and gross margin are primarily affected by Medexus's supply and distribution costs. These costs include the supply prices and royalties paid to third parties, warehouse and logistics expenses for product inventory, and allowances for potential product returns. In the case of IXINITY, the rights to which Medexus owns outright, these costs include manufacturing costs charged by third-party contract manufacturers, which are subject to periodic increases in accordance with the terms of Medexus's contracts; costs associated with manufacturing events such as low-yield or failed batches; and royalty payment obligations assumed in connection with the February 2020 acquisition of Aptevo BioTherapeutics LLC, which are based on a percentage of annual net sales and are expected to constitute a low double-digit percentage of IXINITY net sales from September 2022 through the remaining life of the IXINITY patent portfolio.

Medexus also includes amortization of product licenses as a component of cost of goods sold. This amortization was \$1.4 million and \$4.3 million for the three- and nine-month periods ended December 31, 2022 compared to \$1.4 million and \$4.3 million for the three- and nine-month periods ended December 31, 2021.

Selling and administrative expense

(Amounts in millions)	Three-month periods ended December 31			Nine-month periods ended December 31		
	2022	2021	Change	2022	2021	Change
Selling and administrative expense	\$11.9	\$10.7	11.2%	\$36.9	\$34.1	8.2%

The \$1.2 million and \$2.8 million increase in selling and administrative expense for the three- and nine-month periods ended December 31, 2022 compared to the three- and nine-month periods ended December 31, 2021 was primarily attributable to investments in personnel and infrastructure to support the sale of Gleolan in the United States, partially offset by targeted reductions in general & administrative expenses in light of the ongoing delay in the FDA's review of the treosulfan NDA. Medexus also continues to seek opportunities to optimize its deployment of sales and marketing resources. For example, Medexus has realized continued strong performance in its Rasuvo product with moderate sales force allocation.

The following table provides additional detail on the primary components of Medexus's selling and administrative expense discussed above.

(Amounts in millions)	Three-month periods ended December 31			Nine-month periods ended December 31		
	2022	2021	Change	2022	2021	Change
Employee benefits	\$6.1	\$5.5	10.9%	\$18.4	\$16.4	12.2%
Sales and marketing	\$2.6	\$2.0	30.0%	\$8.7	\$7.7	13.0%
Regulatory, business development	\$1.5	\$1.3	15.4%	\$4.6	\$3.7	24.3%
General and administrative	\$1.7	\$1.8	(5.6)%	\$5.2	\$6.3	(17.5)%

Research and development

(Amounts in millions)	Three-month periods ended December 31			Nine-month periods ended December 31		
	2022	2021	Change	2022	2021	Change
Research and development	\$0.7	\$1.0	(30.0)%	\$2.2	\$5.0	(56.0)%

The \$0.3 million and \$2.8 million decrease in research and development expense for the three- and nine-month periods ended December 31, 2022 compared to the three- and nine-month period ended December 31, 2021 was primarily attributable to further reductions in investments in the IXINITY phase 4 clinical trial as it approaches its analysis and clinical study report stage. Medexus continues to invest a moderate amount of additional capital in connection with its IXINITY manufacturing process improvement initiative.

Operating income or loss

As a result of the factors described above, operating income was \$2.9 million and \$4.9 million for the three- and nine-month periods ended December 31, 2022, an increase of \$3.2 million and \$17.4 million compared to operating loss of \$0.3 million and \$12.5 for the three- and nine-month periods ended December 31, 2021.

Medexus continues to evaluate its management structure and operating expenses in light of the ongoing delay in the FDA's review of the treosulfan NDA. In connection with this ongoing evaluation, Medexus implemented a restructuring plan in October 2022 and incurred termination benefits paid to departing personnel, which are considered to be outside the normal course of

business and are excluded from Adjusted EBITDA. (See “Reconciliation of Adjusted EBITDA to Net Income (Loss)”.)

Net income or loss and adjusted net income or loss

As a result of the factors described above, net loss was \$1.5 million and \$5.6 million for the three- and nine-month periods ended December 31, 2022, an increase of \$0.3 million and a decrease of \$8.0 million compared to net loss of \$1.2 million and net income of \$2.4 million for the three- and nine-month periods ended December 31, 2021.

Adjusted net loss was \$0.9 million and \$7.3 million for the three- and nine-month periods ended December 31, 2022, an increase of \$2.5 million and \$12.1 million compared to adjusted net loss of \$3.4 million and \$19.4 million for the three- and nine-month periods ended December 31, 2021.

Adjusted net loss is adjusted for the unrealized loss (gain) on the fair value of the embedded derivatives in the Convertible Debentures that is included in net loss. See “Preliminary Notes—Non-GAAP measures” and “Reconciliation of Adjusted Net Income (Loss) and Adjusted EBITDA to Net Income (Loss)”.

Adjusted EBITDA

Adjusted EBITDA was \$5.2 million and \$11.3 million for the three- and nine-month periods ended December 31, 2022 compared to \$1.9 million and \$(5.0) million for the three- and nine-month periods ended December 31, 2021. The \$3.3 million and \$16.3 million increase was primarily attributable to the increases in net sales discussed above, the reduction in research & development costs discussed above, and an increase in gross margin.

Adjusted EBITDA is adjusted for a number of non-cash charges that are included in net loss and adjusted net loss. See “Preliminary Notes—Non-GAAP measures” and “Reconciliation of Adjusted Net Income (Loss) and Adjusted EBITDA to Net Income (Loss)”.

SUMMARY OF QUARTERLY RESULTS

The following table sets out summary unaudited quarterly financial information for each of the eight financial quarters through and including the financial quarter ended December 31, 2022.

(Amounts in \$ '000s, except per share amounts)

Three-months ended	31-Dec-22	30-Sept-22	30-Jun-22	31-Mar-22	31-Dec-21	30-Sept-21	30-Jun-21	31-Mar-21
Total Revenue	28,731	27,686	23,046	20,263	21,270	17,901	17,267	17,639
Gross Profit	15,933	16,144	12,944	10,114	11,501	9,388	6,924	8,813
Selling and Administrative Expenses	11,878	12,861	12,125	9,892	10,679	11,736	11,725	10,252
Research and Development	693	856	661	834	1,035	1,773	2,231	2,016
Transaction-Related Fees	–	144	28	53	33	–	–	634
Termination Benefits	372	238	–	–	–	784	–	345
Operating Income (Loss)	2,900	1,947	33	(2,504)	(339)	(4,991)	(7,162)	(4,566)
Net Income (Loss)	(1,507)	(2,730)	(1,552)	(5,287)	(1,150)	10,145	(6,587)	(10,490)
Net Income (Loss) per share – Basic	(0.07)	(0.14)	(0.07)	(0.27)	(0.07)	0.53	(0.34)	(0.63)
Net Income (Loss) per share – Diluted	(0.07)	(0.14)	(0.07)	(0.27)	(0.07)	0.52	(0.34)	(0.63)
Adjusted Net Loss*	(861)	(2,843)	(3,637)	(4,619)	(3,389)	(6,135)	(9,833)	(5,158)
Adjusted Net Loss per share* - Basic and Diluted	(0.07)	(0.14)	(0.07)	(0.23)	(0.17)	(0.32)	(0.51)	(0.32)
Adjusted EBITDA*	5,223	4,197	1,906	1,081	1,916	(2,016)	(4,912)	(1,620)
Cash provided (used) by operations	(2,204)	912	(4,015)	3,782	(1,718)	3,571	(6,815)	4,203
Cash & cash equivalents, end of period	9,273	9,647	7,285	10,018	9,571	8,137	10,199	18,704
Assets	146,320	142,308	136,399	139,225	138,131	137,210	142,970	148,513
Long-term liabilities	30,086	60,609	69,298	73,325	68,350	70,145	89,198	90,558
Dividends	–	–	–	–	–	–	–	–

* See "Preliminary Notes—Non-GAAP measures" and "Reconciliation of Adjusted EBITDA to Net Income (Loss)".

Note regarding period-to-period variations

Medexus's total revenue is minimally affected by seasonality in net sales of Rupall, one of Medexus's current leading products by revenue, depending on the severity and timing of allergy seasons across Canada.

Medexus's research and development expense has varied in large part due to the timing of expenditures relating to the IXINITY clinical trial and IXINITY manufacturing process improvement initiative discussed under "Operational Highlights—Product highlights—Current leading products by revenue—IXINITY".

Pharmacy and wholesale customers of IXINITY have returned to normal buying patterns that are better aligned with patient unit demand following a period of lower net sales as those customers worked through inventory on hand. Medexus believes that this development will reduce inorganic fluctuations in quarterly sales.

Medexus acquired the exclusive right to commercialize Gleolan in the United States in March 2022 and successfully completed the full transition of U.S. commercial responsibility to Medexus in August 2022. September 2022 was therefore the first full month, and the three-month period ended December 31, 2022 was the first full fiscal quarter, in which Medexus recognized 100% of Gleolan net sales in the company's total revenue.

COMPANY STRATEGY AND OUTLOOK

Business strategy

Medexus focuses on commercialization of an existing portfolio of pharmaceutical products previously licensed or acquired from third parties. These existing products have primarily driven Medexus's performance to date. Medexus also focuses on opportunities to complement its existing product portfolio by licensing and acquiring new products. Medexus therefore does not make significant investments in research and development. Medexus generally purchases finished products manufactured by third-party licensors and distributes them in the United States or Canada. Medexus uses third-party contract manufacturers for products that Medexus owns outright.

Corporate organizational structure

Medexus Pharmaceuticals Inc., a Canada corporation, operates Medexus's business operations in Canada. It also owns 100% of the issued and outstanding shares of MI Acquisitions, Inc., a Delaware corporation.

MI Acquisitions, Inc. is an intermediate holding company that does not engage in any operating activities. MI Acquisitions, Inc. owns 100% of the issued and outstanding shares of Medexus Pharma, Inc., a Delaware corporation.

Medexus Pharma, Inc. operates Medexus's business operations in the United States. It is also the sole member (owning 100% of the membership interests) of Aptevo BioTherapeutics LLC, a Delaware limited liability company.

Aptevo BioTherapeutics LLC owns Medexus's rights to IXINITY. It otherwise does not engage in operating activities.

Industry trends

Medexus believes that a number of trends in the pharmaceutical industry create a favorable environment for the licensing or acquisition and distribution of commercial-stage assets.

Demographics

Growth of the population in general and aging of the population in particular will continue to drive demand for pharmaceutical therapies. Favorable perception of branded products will result in sustained opportunities for select established brand assets and promotional stage products, including those within Medexus's product portfolio.

Healthcare reform: U.S. Patient Protection and Affordable Care Act

The U.S. Patient Protection and Affordable Care Act has resulted in an increase of access to healthcare services and treatments in the United States. This trend may continue but will be attenuated by changes in the legal and political environment, including changes in formulary management practices.

Commercial pricing pressures

Pricing and access pressures in the commercial sector continue to be significant. Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Many employers have adopted high deductible health plans, which can increase out-of-pocket costs for medicines. This trend is likely to continue. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates, and a reduction in demand for Medexus's products. Pricing pressures also may occur as a result of highly competitive insurance markets. Healthcare provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.

Managed care organizations (MCOs)

The evolution of managed care in the United States has been a major factor in the competitiveness of the healthcare marketplace. A significant percentage of the U.S. population now have some form of health insurance coverage, and the marketing of prescription drugs to both consumers and the entities that manage coverage in the United States continues to grow in importance. In particular, the influence of MCOs has increased in recent years due to the growing number of patients receiving coverage through MCOs. At the same time, consolidation in the MCO industry has resulted in fewer, even larger MCOs, which enhances those MCOs' ability to negotiate pricing and increases their importance to Medexus's business. Since MCOs seek to contain and reduce healthcare expenditures, their growing influence has increased pressure on drug prices as well as revenues.

Medicare coverage

Often, established brand pharmaceutical products subject to Medicare or Medicaid or falling under the Federal Supply Schedule may still be competitive in price to alternatives due to mandatory rebates and average manufacturer price calculation rules prescribed by U.S. law. The Federal Supply Schedule is a list of contractors that have been awarded a contract by the U.S. General Services Administration, an independent agency of the U.S. government, and those contractors can be used by all U.S. federal agencies. Medexus continues to evaluate the potential impact of the Inflation Reduction Act of 2022, which became effective in August 2022; however, based on the company's preliminary assessments, the near-term impact is expected to be limited.

Product opportunities

Medexus expects that drug development companies without commercial infrastructure in the United States and Canada will continue seeking commercialization partners to promote their products in those markets.

Medexus also believes that large pharmaceutical companies will continue to focus on their core therapeutic areas, meaning that these companies will divest non-core or non-strategic products, many of which could fall into the product lifecycle stages on which Medexus focuses its business development activities.

Customers

Medexus has a limited number of direct customers, and the majority of Medexus's sales are to large national wholesalers, specialty pharmacies, and healthcare institutions. For financial year 2022, two customers (both of which were large national wholesalers) each individually accounted for more than 10% of Medexus's total revenue, together accounting for approximately 59% of Medexus's total revenue. See "Risk Factors—Risks Relating to the Business—Dependence on a Small Number of Customers" in the AIF.

Manufacturing, supply and distribution

Medexus focuses on managing the production and distribution of pharmaceutical products that the company commercializes. Medexus generally purchases finished products manufactured by third-party licensors and distributes them in the United States or Canada. Medexus uses third-party contract manufacturers for products that Medexus owns outright. Medexus relies on third-party logistics providers to administer distribution logistics processes in both the United States and Canada. This includes warehousing, order processing, shipping, and invoicing and collections.

Medexus and its third-party partners are, and will continue to be, subject to extensive government regulation in connection with the manufacture, supply, and distribution of pharmaceutical products. Products that Medexus commercializes must be manufactured in facilities and using processes, methods, and equipment that comply with the requirements of the FDA (for products commercialized in the United States) or Health Canada (for products commercialized in Canada). See "Risk Factors—Risks Relating to the Business—Reliance on Third Parties for the Manufacture and Supply of Products" in the AIF.

LIQUIDITY AND CAPITAL RESOURCES

Overview

Medexus continually and proactively monitors its liquidity position. Medexus seeks to manage the company's liquidity and capital resources to meet the demands of its operations in light of changes in business conditions and otherwise as appropriate in light of the underlying risk of the company's assets. Failure to generate sufficient cash flows from operations or from additional financing activities would have an adverse effect on Medexus's ability to fulfill its financial obligations and achieve its business objectives. Meaningful near-term liquidity considerations for the company include maintaining sufficient financial resources to –

- make regulatory milestone payments to the company's third-party licensors if and when they become due;
- make interest and principal payments in respect of the company's debt financing arrangements;
- carry on the continued development and commercialization of existing products;
- secure new business opportunities and product registrations, including funding any associated clinical development programs;
- prevent or mitigate delays or challenges in supply of the company's products; and
- comply with regulatory requirements, including those relating to manufacturing and distribution of the company's products.

Under the terms of Medexus's February 2021 exclusive license agreement relating to treosulfan (**U.S. Treosulfan Agreement**), it was agreed that, upon an FDA approval of treosulfan, Medexus would become obligated to pay a milestone amount to medac of between \$15.0 million and \$45.0 million depending on the terms of the FDA's approval. Under the terms of a September 2021 amendment to the U.S. Treosulfan Agreement, it was further agreed that this amount would include repayment of a \$2.5 million credit received from medac in September 2021 in respect of previously paid milestone amounts. However, in light of the ongoing delay in the FDA's review of the treosulfan NDA, which Medexus expects to continue beyond the agreed FDA approval outside date, the U.S. Treosulfan Agreement provides that the amount of this milestone payment, together with future sales-based milestones, will be subject to renegotiation and adjustment as to reflect changes in the perceived value of the product, including as a result of increases or decreases in patient population, changes in treatment landscape, changes in competition, and changes in market access as a result of the delay in securing FDA approval of the NDA.

Sources of liquidity

As of December 31, 2022, Medexus had \$10.1 million (March 31, 2022 – \$11.2 million) of available liquidity as follows –

- cash and cash equivalents of \$9.3 million (March 31, 2022 – \$10.0 million); and

- available credit of \$0.8 million (March 31, 2022 – \$1.2 million) under the Revolving Loan Agreement (defined below).

The loans outstanding under Medexus's May 2020 revolving loan credit agreement with a syndicate of lenders represented by MidCap Funding IV Trust as agent (**Revolving Loan Agreement**) and February 2020 term loan credit agreement with a syndicate of lenders represented by MidCap Financial Trust as agent (**Term Loan Agreement** and together with the Revolving Loan Agreement the **Credit Agreements**) (discussed in the AIF) are expected to mature in July 2023. Additionally, Medexus's Convertible Debentures will mature on October 16, 2023, with repayment to be made in cash or, at Medexus's option, in whole or in part in common shares of the company. Accordingly, the total amount of those loans and Convertible Debentures appear in the current portion of long-term debt in Medexus's interim consolidated statement of financial position as at December 31, 2022. Medexus, together with its third-party advisors, is actively evaluating options with respect to its capital structure, including its debt financing arrangements, and is in the advanced stages of a competitive process that has involved a number of highly interested capital providers. Medexus has been successful in securing third-party financing in the past. However, there can be no assurance that the company will be able to secure similar third-party financing in the future, or that these sources of capital will be available to Medexus on terms acceptable to the company.

Cash flows

(Amounts in \$ '000s)

Three-month periods ended December 31	2022	2021
Cash used by operating activities	(2,204)	(1,718)
Cash used by investing activities	(538)	(353)
Cash provided by financing activities	2,416	3,477
Increase (decrease) in cash position during the period	(326)	1,406
Impact of foreign exchange	(48)	28
Cash and cash equivalents, beginning of period	9,647	8,137
Cash and cash equivalents, end of period	9,273	9,571

(Amounts in \$ '000s)

Nine-month periods ended December 31	2022	2021
Cash used by operating activities	(5,307)	(4,962)
Cash used by investing activities	(1,026)	(6,359)
Cash provided by financing activities	5,807	2,203
Decrease in cash position during the period	(526)	(9,118)
Impact of foreign exchange	(219)	(15)
Cash and cash equivalents, beginning of period	10,018	18,704
Cash and cash equivalents, end of period	9,273	9,571

Operating activities

Cash used by operating activities was \$2.2 million for the three-month period ended December 31, 2022 compared \$1.7 million for the three-month period ended December 31, 2021. Cash used by operating activities for the three-month period ended December 31, 2022 comprised a net income, adjusted for non-cash expenditures, of \$4.4 million (2021 – \$1.5 million) and a change in working capital of \$(6.6) million (2021 – \$(3.2) million).

Cash used by operating activities was \$5.3 million for the nine-month period ended December 31, 2022 compared \$5.0 million for the nine-month period ended December 31, 2021. Cash used by operating activities for the nine-month period ended December 31, 2022 comprised a net income,

adjusted for non-cash expenditures, of \$10.0 million (2021 – \$(6.9) million) and a change in working capital of \$(15.3) million (2021 – \$1.9 million).

Investing activities

Cash used by investing activities was \$0.5 million and \$1.0 million for the three- and nine-month periods ended December 31, 2022 compared to \$0.4 million and \$6.4 million for the three- and nine-month periods ended December 31, 2021.

Financing activities

Cash provided by financing activities was \$2.4 million and \$5.8 million for the three and nine-month periods ended December 31, 2022 compared to \$3.5 million and \$2.2 million for the three- and nine-month periods ended December 31, 2021, due primarily to net draws on the Revolving Loan Agreement.

OFF-BALANCE SHEET ARRANGEMENTS

Medexus had no off-balance sheet arrangements as of December 31, 2022.

TRANSACTIONS WITH RELATED PARTIES

Below is a summary of transactions during the three- and nine-month periods ended December 31, 2022 in which Medexus participated and in which any related party as determined under IFRS had a direct or indirect material interest. Medexus views the following transactions with related parties as having occurred in the normal course of the company's operations.

- Medexus pays warehouse fees to a company in which an executive officer holds a 50% equity interest for storage and distribution services in respect of certain of Medexus's products in Canada. These warehouse fees totaled \$33,000 and \$177,000 during the three- and nine-month periods ended December 31, 2022, compared to \$41,000 and \$178,000 during the three- and nine-month periods ended December 31, 2021.
 - Medexus incurs interest on Convertible Debentures that are owned or controlled, directly or indirectly, by three of the company's directors. All interest payments are made in accordance with the terms of the Convertible Debentures. Interest expense related to these three individuals totaled an aggregate of \$69,000 and \$214,000 during the three- and nine-month periods ended December 31, 2022, compared to \$73,000 and \$220,000 during the three- and nine-month periods ended December 31, 2021.
-

RECONCILIATION OF ADJUSTED NET INCOME (LOSS) AND ADJUSTED EBITDA TO NET INCOME (LOSS)

The following tables are derived from and should be read together with Medexus's consolidated statement of operations for the three- and nine-month periods ended December 31, 2022. This supplementary disclosure is intended to more fully explain disclosures related to Adjusted Net Loss and Adjusted EBITDA and provides additional information related to Medexus's operating performance. See "Preliminary Notes—Non-GAAP measures".

(Amounts in \$ '000s)	Three-month periods ended December 31		Nine-month periods ended December 31	
	2022	2021	2022	2021
Net income (loss)	(1,507)	(1,150)	(5,635)	2,408
Add back:				
Unrealized gain on fair value of derivatives	646	(2,239)	(1,706)	(21,765)
Adjusted net loss	(861)	(3,389)	(7,341)	(19,357)

	Three-month periods ended December 31		Nine-month periods ended December 31	
	2022	2021	2022	2021
(Amounts in \$ '000s)				
Net loss	(1,507)	(1,150)	(5,635)	2,408
Add back:				
Depreciation and amortization (property, equipment, intangible assets)	1,515	1,500	4,594	4,628
Interest expense	3,552	3,160	9,994	9,116
Income tax recovery	547	(94)	582	(2,619)
EBITDA	4,107	3,416	9,535	13,533
Add back:				
Share-based compensation	436	722	1,070	2,035
Transaction-related fees	–	33	172	33
Termination benefits	372	–	610	784
Foreign exchange loss	(338)	(16)	1,645	368
Unrealized gain on fair value of derivatives	646	(2,239)	(1,706)	(21,765)
Adjusted EBITDA	5,223	1,916	11,326	(5,012)

CRITICAL ACCOUNTING ESTIMATES, JUDGMENTS, AND ASSUMPTIONS

The preparation of the Company's condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities and reported amounts of revenues and expenses during the period. These estimates and assumptions are based on historical experience, expectations of the future, and other relevant factors and are reviewed regularly. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future period affected. Actual results may differ from these estimates.

A description of the Company's significant estimates, judgements and assumptions is included in Note 2 to the Company's interim consolidated financial statements for the three- and nine-month periods ended December 31, 2022.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

The carrying values of cash, amounts receivable, advances to related parties, loans receivable, accounts payable and accrued liabilities, and advances from related parties approximate their carrying values due to the immediate or short-term nature of these instruments.

IFRS 13, *Fair Value Measurement*, establishes a fair value hierarchy that prioritizes the input to valuation techniques used to measure fair value as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Medexus's financial instruments consist of cash, other current assets, accounts payable, derivative liability, and promissory notes. The fair values of other current assets, accounts payable, related parties payable, Convertible Debentures, and promissory note approximate their carrying values either due to their current nature or current market rates for similar instruments. Cash is measured at fair value on a recurring basis using level 1 inputs. Derivative liability is measured at fair value on a recurring basis using level 3 inputs.

DISCLOSURE OF OUTSTANDING SHARE DATA

Summary

Medexus's authorized share capital consists of an unlimited number of Common Shares and an unlimited number of preferred shares. As at February 8, 2023, Medexus had 20,139,018 Common Shares and no preferred shares issued and outstanding.

In addition, as at February 8, 2023, the following number of Common Shares were issuable in accordance with the terms of convertible securities (including equity incentive compensation awards) issued by Medexus –

- 9,891,907 Common Shares issuable upon conversion of the Convertible Debentures;
- 2,233,918 Common Shares issuable upon exercise of the 2018 Warrants;
- 2,290,844 Common Shares issuable upon exercise of the 2021 Warrants;
- 232,647 Common Shares issuable upon exercise of the 2021 Underwriter Warrants;
- 270,000 Common Shares issuable upon exercise of the MidCap Warrants;
- 457,163 Common Shares issuable upon exercise of RSUs (defined below);
- 732,736 Common Shares issuable upon exercise of PSUs (defined below) (assuming vesting at 100%); and
- 1,033,248 Common Shares issuable upon exercise of Options (defined below).

Description of securities

The following sections set out a description of the material characteristics of each class of security that is issued and outstanding as of the date of this MD&A.

Common Shares

Each Common Share entitles the holder to one vote per share. The holders of Common Shares are entitled to receive notice of meetings of shareholders of Medexus and to vote at the meeting. Holders of Common Shares are entitled to receive, as and when declared by the Board, dividends in such amounts as may be determined by the Board. Holders of Common Shares have the right to receive any remaining residual asset value of Medexus in the event of a liquidation, dissolution, or winding-up of Medexus, whether voluntary or involuntary.

Convertible Debentures and 2018 Warrants

In October 2018, in connection with the acquisition of Medexus Inc. and medac Pharma, Inc. (now known as Medexus Pharma, Inc.), Medexus issued C\$42.0 million aggregate principal amount of Convertible Debentures under a convertible debenture indenture with Computershare Trust Company of Canada as trustee. As of December 31, 2022, C\$41.5 million aggregate principal amount remained issued and outstanding.

The Convertible Debentures bear interest at an annual rate equal to 6.00%. Interest on the issued and outstanding Convertible Debentures is payable semiannually in arrears on March 31 and December 31. The Convertible Debentures mature on October 16, 2023. At maturity, Medexus will be obligated to repay 125% of the aggregate principal amount of the then issued and outstanding Convertible Debentures plus any accrued and unpaid interest. Subject to any required approvals, Medexus may satisfy these amounts in cash, Common Shares, or a combination of the two. The Convertible Debentures are senior to Medexus's equity securities, including the Common Shares, and subordinate to Medexus's senior secured debt facilities, including the Credit Agreements.

The Convertible Debentures are convertible into units (**Conversion Units**) at a conversion price of C\$6.30, subject to adjustment as provided under the terms of the Convertible Debentures. Each Conversion Unit consists of one Common Share and one half of one warrant to purchase one Common Share (each whole warrant a **2018 Warrant**) exercisable at a price of C\$9.45 per whole 2018 Warrant until October 16, 2023.

Medexus issued a further 2,233,918 2018 Warrants under a warrant indenture dated October 2018 (**2018 Warrant Indenture**) with Computershare Trust Company of Canada as warrant agent.

As of December 31, 2022, holders of Convertible Debentures had received 72,062 Conversion Units upon conversion of Convertible Debentures, comprising 72,062 Common Shares and 2018 Warrants to purchase an additional 36,030 Common Shares. If all remaining Convertible Debentures were converted in full (without giving effect to accrued interest, which Medexus may elect to pay in cash, Common Shares, or a combination of the two), then holders would receive 6,594,604 Conversion Units, comprising 6,594,604 Common Shares and 2018 Warrants to purchase an additional 3,297,303 Common Shares.

2021 Warrants and 2021 Underwriter Warrants

In February 2021, Medexus completed a public offering of units at a price of C\$7.10 per unit (**2021 Offering**) through a syndicate of underwriters represented by Raymond James Ltd. and Stifel GMP as co-lead underwriters and joint bookrunners. Medexus received aggregate gross proceeds of approximately C\$32.5 million, including the full exercise by the underwriters of their overallotment option. The units issued in the 2021 Offering each consisted of one Common Share and one half of one warrant to purchase one Common Share (each whole warrant a **2021 Warrant**) exercisable at a price of C\$10.00 per whole 2021 Warrant until February 23, 2023. Medexus issued a total of 2,290,844 2021 Warrants in the 2021 Offering.

Medexus also issued, to the underwriters of the 2021 Offering, an aggregate of 232,647 warrants to purchase one Common Share (**2021 Underwriter Warrants**) exercisable at a price of C\$7.10 per 2021 Underwriter Warrant until February 23, 2023.

Medexus issued the 2021 Warrants and the 2021 Underwriter Warrants under a warrant indenture dated February 23, 2021 (**2021 Warrant Indenture**) with Computershare Trust Company of Canada as warrant agent.

MidCap Warrants

In February 2020, in connection with the Term Loan Agreement, Medexus issued, to an affiliate of MidCap Financial Trust, 134,290 warrants to purchase one Common Share (**MidCap Warrants**) exercisable at a price of C\$4.00 until the maturity of the loan outstanding under the Term Loan Agreement in July 2023 (unless otherwise extended in accordance with the terms of the Term Loan Agreement).

In September 2022, in connection with an amendment to the Revolving Loan Agreement, Medexus issued, to an affiliate of MidCap Financial Trust, an additional 135,710 MidCap Warrants, exercisable at a price of C\$1.02, and amended the existing MidCap Warrants to reduce the exercise price to C\$1.02. The MidCap Warrants will be exercisable until the maturity of the loans outstanding under the Term Loan Agreement, which is expected to occur in July 2023 unless extended in accordance with the terms of the Term Loan Agreement.

Securities issued under the Equity Plans

Medexus issues equity incentive compensation awards to eligible participants under the company's equity incentive compensation plans (**Equity Plans**): the Medexus Long Term Incentive Plan, which was adopted at the company's annual meeting of shareholders in September 2022, and, previously, the company's 2018 Omnibus Equity Incentive Plan.

RSUs

Since December 2018, Medexus has issued restricted stock units (**RSUs**) to participants under the Equity Plans. The RSUs generally vest in equal amounts upon the first, second, third, and fourth anniversaries of the grant date. RSUs issued annually to directors generally vest on the date of the following annual general meeting of shareholders. Each vested RSU entitles the holder to receive one Common Share in accordance with the Equity Plans and the terms of the holder's RSU award agreement.

PSUs

Since October 2020, Medexus has issued performance share units (**PSUs**) to participants under the Equity Plans. The PSUs will vest if Medexus achieves a number of predetermined objectives during performance periods that generally extend over multiple financial years. Each vested PSU will represent an obligation of Medexus to issue one Common Share in accordance with the Equity Plans and the terms of the holder's PSU award agreement.

Options

Since October 2020, Medexus has issued options to purchase Common Shares (**Options**) to participants under the Equity Plans. The Options generally vest in equal amounts upon the grant date and the first, second, third, and fourth anniversaries of the grant date. Options issued annually to directors generally vest on the date of the following annual general meeting of shareholders. Each vested Option entitles the holder to receive one Common Share by delivering an exercise notice and payment of the exercise price in accordance with the Equity Plans and the terms of the holder's Option award agreement.

RISK FACTORS AND RISK MANAGEMENT

Medexus is subject to a number of risks and uncertainties. A risk is the possibility that an event might happen in the future that could have a negative effect on the company's financial condition, financial performance, or business. The Board has overall responsibility for overseeing Medexus's evaluation and mitigation of these risks and periodically reviews Medexus's risk management practices.

A comprehensive discussion of the principal risks and uncertainties that Medexus faces are described under the heading "Risk Factors" in Medexus's most recent AIF, which is available on Medexus's issuer profile on SEDAR at www.sedar.com. Management believes that the risks and uncertainties set out therein have not materially changed. However, those risks are not the only risks facing Medexus, its business, and the pharmaceutical industry as a whole. Additional risks not currently known to Medexus, or that the company currently deems immaterial, may also adversely affect Medexus's operations.

CONTROLS AND PROCEDURES

Disclosure controls and procedures

Medexus's management are together responsible for establishing and maintaining disclosure controls and procedures as defined in National Instrument 52-109 – Certification of Disclosure in Issuers' Annual and Interim Filings (**NI 52-109**). Medexus's management have together designed such a system of disclosure controls and procedures to provide reasonable assurance that material information with respect to Medexus is made known to them and information required to be disclosed by Medexus in its annual filings, interim filings, or other reports filed, furnished, or submitted by the company under securities laws is recorded, processed, summarized, and reported within the time periods required by the relevant securities laws.

Internal controls over financial reporting

Medexus's management are together responsible for establishing and maintaining internal controls over financial reporting as defined in NI 52-109 (**ICFR**). Medexus's management have together designed such a system of ICFR to provide reasonable assurance regarding the reliability of financial reporting for external purposes in accordance with IFRS. The control framework that Medexus's management used to design the company's ICFR is set out in Internal Control–Integrated Framework (2013) as issued by the Committee of Sponsoring Organizations of the Treadway Commission. There have been no changes in Medexus's ICFR during the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, Medexus's ICFR.

Limitations of controls and procedures

Any disclosure controls and procedures or internal controls over financial reporting, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, they cannot provide

absolute assurance that all control issues and instances of fraud, if any, within Medexus have been prevented or detected.

These inherent limitations include the reality that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of individuals, by collusion of two or more people, or by unauthorized override of the control. The design of any control system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Accordingly, because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

ADDITIONAL INFORMATION

SEDAR

Additional information about Medexus may be found on SEDAR at www.sedar.com. In particular, additional information about Medexus's business and operations is provided in Medexus' most recent annual information form, and additional financial information is provided in Medexus's consolidated financial statements as of and for the three- and nine-month periods ended December 31, 2022, together with the related independent auditor's report dated February 8, 2023, each of which have been filed on SEDAR.

Other information

Medexus seeks to achieve broad non-exclusionary distribution of information to the public and comply with its fair disclosure obligations. In addition to its filings on the company's SEDAR profile at www.sedar.com, Medexus announces material information to the public through a variety of means, including press releases, public conference calls, and webcasts. Medexus also maintains a corporate website at www.medexus.com (a uniform resource locator, or website address, provided as an inactive textual reference only) and social media accounts on LinkedIn and Twitter. Medexus uses these various means as channels of distribution of information about the company. Information Medexus provides through these channels may be deemed material. Investors should monitor Medexus's corporate website, including press releases posted to the website, and social media accounts in addition to Medexus's public filings, conference calls, and webcasts. However, information contained on or accessible through Medexus's corporate website or social media accounts is not a part of this MD&A and is not incorporated by reference into this MD&A or any of Medexus's public filings.